Table 5.

Therapeutics targeting inhibitory receptor/ligands being tested in clinical trials.

Treatment	Other name	Conditions(Phase)
CTLA-4Ig	Abatacept	Type 1 diabetes mellitus (II), psoriasis vulgaris (I+II), lupus nephritis (II), lupus erythematosus, systemic (II), rheumatoid arthritis (I+II), Wegener's granulomatosis (II+III), Takayasu's arteritis (I+II), giant cell arteritis (I+II), multiple sclerosis (II), allergic asthma (II).
	Belatacept	Rheumatoid arthritis (I+II+III)
(CTLA-4 IgG4m)	RG2077	Lupus erythematosus, systemic (I+II), lupus nephritis (I+II).
Anti-CTLA-4	MDX-010/ Ipilimumab	Synovial Sarcoma (II), wilm's tumor (I), lymphoma (I), neuroblastoma (I), melanoma (I+III), malignant fibrous histiocytoma of bone (I), kidney cancer (I), prostate cancer (I), high risk stage III melanoma (III), leukemia (I), lung Cancer (I), myelodysplastic syndromes (I), ovarian cancer (I), pancreatic cancer (II), extensive stage small cell lung cancer (II).
	CD-675,206/ Tremelimumab	Melanoma (II), prostatic neoplasms (I), hepatocellular carcinoma (I), hepatitis C virus chronic infection (I), bladder cancer (I), renal cell carcinoma (II).
Anti-CD80	IDEC-114	Non-Hodgkin's lymphoma (I+II).
	Galiximab	Non-Hodgkin's lymphoma (I+III).
Anti-PD-1	MDX1106	melanoma (I), hepatitis C (I).
	CT-011	Prostatic neoplasms (II), breast cancer(I), colon cancer (I), pancreatic cancer (I), sarcoma (I), ovarian cancer (I), renal cell carcinoma (II), acute myelogenous leukemia (II), multiple myeloma (II).
	BMS-936558	Renal cell carcinoma (I), non-small cell lung cancer (I).
	ONO-4538	malignant solid tumor (I).
Anti-PD-L1	BMS-936559	Stage III or IV melanoma, non-Hodgkin's lymphoma (I), Hodgkin Lymphoma (I), multiple myeloma (I), chronic myelogenous leukemia (I).
Anti-PD-L2	rHIgM12B7	Melanoma (I).

This information was obtained from clinicaltrails.gov.